AMPK agonists(AMP activated protein kinase agonists), P-gp inhibitors(P-glycoprotein 1 inhibitors), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists)

+ [1]

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

Boryung Corp.

Active Organization-

Inactive Organization

Boryung Corp.

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC19H21ClN2O3S

InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N

CAS Registry112529-15-4

View All Structures (2)

Clinical Trials associated with Dapagliflozin/Pioglitazone

NCT05411965

/ CompletedPhase 1

A Randomized, Open-label, Single Dose, Two-way Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR3003" and Co-administration of "BR3003B" and "BR3003C" in Healthy Volunteers.

To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.

Start Date28 Apr 2022

Sponsor / Collaborator

Boryung Corp.

100 Clinical Results associated with Dapagliflozin/Pioglitazone

100 Translational Medicine associated with Dapagliflozin/Pioglitazone

100 Patents (Medical) associated with Dapagliflozin/Pioglitazone

Literatures (Medical) associated with Dapagliflozin/Pioglitazone

01 Feb 2025·Diabetes, Obesity and Metabolism

Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients

Article

Author: DeFronzo, Ralph A. ; Triplitt, Curtis ; YueJuan, Qin ; Hansis‐Diarte, Andrea ; Barkhordarian, Maryam ; Chavez, Alberto ; Cersosimo, Eugenio ; Baskoy, Gozde

AbstractAimsTo investigate the effect of sodium‐glucose co‐transporter 2 inhibitor [SGLT‐2i] therapy on renal haemodynamics in T2D patients with glomerular hyperfiltration.Materials and MethodsSixty T2D patients with elevated [HYPER] and normal [NORMO] GFR were randomized to dapagliflozin 10 mg/day [DAPA/HYPER, n = 15; DAPA/NORMO, n = 15] or to metformin/glipizide [CONTROL/HYPER, n = 15; CONTROL/NORMO, n = 15] to reach similar glycaemic control after 4 months. GFR was measured with Iohexol and hyperfiltration was empirically defined as >125 mL/min/1.73 m2. GFR, renal plasma flow [RPF], mean arterial pressure [MAP], filtration fraction [FF], and renal vascular resistance [RVR] were determined before/after therapy.ResultsHbA1c decreased similarly in all 4 groups. GFR declined by ~18% in DAPA/HYPER and by ~7% in DAPA/NORMO and did not change in CONTROLS (p < 0.05 vs. DAPA). RPF remained unchanged in all four groups. Thus, FF (%) declined from 0.23 ± 0.01 to 0.18 ± 0.01 in DAPA/HYPER and from 0.17 ± 0.01 to 0.15 ± 0.01 in DAPA/NORMO and remained unchanged in CONTROLS (p < 0.05 vs. DAPA). MAP (mmHg) decreased from 95.4 ± 1.4 to 88.1 ± 1.3 in DAPA/HYPER and from 95.6 ± 1.3 to 91.8 ± 0.8 in DAPA/NORMO and remained unchanged in CONTROLS (p < 0.05 vs. DAPA). RVR [mmHg/L/min] declined in DAPA/HYPER (92.7 ± 7.8 to 80.4 ± 6.1) and DAPA/NORMO (90.1 ± 3.0 to 81.4 ± 2.1) but not in CONTROLS (p < 0.05 vs. DAPA).ConclusionsDespite comparable glycaemic control, dapagliflozin treatment, but not metformin and /or glipizide, reduced glomerular hyperfiltration in T2D patients and decreased both filtration fraction and renal vascular resistance. These findings suggest that a post‐glomerular vasodilatory action of SGLT2 inhibitors contributes to their renal protective effect in T2D.

01 Nov 2024·BMJ Open

Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: study protocol for the Dapagliflozin, Exercise Training and physicAl function (DETA) randomised controlled trial

Article

Author: Sargeant, Jack A ; Davies, Melanie J ; Khunti, Kamlesh ; James, Emily ; Baker, Luke ; Bilak, Joanna M ; King, James A ; Wormleighton, Joanne V ; Coull, Nicole A ; Watson, Emma ; Rowlands, Alex ; Ahmad, Ehtasham ; Gulsin, Gaurav Singh ; Yates, Thomas ; McCann, Gerry P ; Redman, Emma

IntroductionSodium-glucose co-transporter 2 inhibitors (SGLT2i) are associated with weight loss, diverse cardiorenal benefits and improved glycaemic control. However, the effects of SGLT2i on physical function and fitness are uncertain. The Dapagliflozin, Exercise Training and physicAl function trial investigates whether the SGLT2i dapagliflozin, alone or in combination with structured exercise training, improves physical function compared with diet-induced weight loss in adults with type 2 diabetes mellitus (T2DM), overweight/obesity and impaired physical function.Methods and analysisThis single-centre randomised controlled trial will assign 1:1:1, 135 adults with T2DM and low physical function to receive one of three treatments: (1) dapagliflozin (10 mg once-daily) alone, (2) dapagliflozin (10 mg once-daily) plus structured exercise training or (3) diet control (where participants are supported to achieve 3% weight loss, equivalent to estimated weight loss with dapagliflozin treatment). Primary and secondary outcomes will be assessed at baseline, 12 and 24 weeks. The primary outcome is the difference in physical function, assessed using the modified Physical Performance Test, between the treatment groups and diet control at 24 weeks. Secondary outcomes include MRI-measured cardiac structure and function, maximal aerobic capacity, resting metabolic rate, device-measured physical activity and sleep, body composition, haemoglobin A1c and cardiovascular risk markers.Ethics and disseminationThe Heath Research Authority (HRA) and the Medicines and Healthcare Products Regulatory Authority (MHRA) Research Ethics Committee have approved the study. The findings of the study will be published in peer-reviewed journals.Trial registration numberISRCTN11459997.EudraCT number2019-004586-41.

American Journal of Cardiovascular Drugs

Real-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus

Article

Author: Birinci, Şuayip ; Colluoglu, Tugce ; Kanik, Arzu ; Sahin, Anil ; Celik, Ahmet ; Yilmaz, Mehmet Birhan ; Ulgu, Mustafa Mahir ; Ural, Dilek ; Ata, Naim

BACKGROUNDSodium-glucose cotransporter-2 inhibitors (SGLT2is) are breakthrough agents for the treatment of type 2 diabetes mellitus (T2DM) and heart failure (HF). However, among patients with HF and T2DM, some uncertainty remains about individual comparisons, including dosing.OBJECTIVESWe aimed to make a real-life individual comparison of SGLT2is among patients with HF and T2DM.METHODSThis was a subgroup analysis of the Turkish Ministry of Health's National Electronic Database for adult patients with HF (TRends-HF). All-cause mortality (ACM) data up to 7 years were evaluated. Patients with HF and T2DM who were prescribed an SGLT2i were identified, and individual doses of empagliflozin 25 mg, empagliflozin 10 mg, and dapagliflozin 10 mg were compared. For individual comparisons, propensity score-matching analysis was generated as 1:1:1, and disease-modifying therapies (DMTs) for HF were considered.RESULTSIn the triple-matched cohort, 1-, 5-, and 7-year survival rates were 95%, 81%, and 76% versus 94%, 78%, and 72% versus 94%, 80%, and 75% for empagliflozin 25 mg, empagliflozin 10 mg, and dapagliflozin 10 mg, respectively. Among patients who were on triple DMT for HF, 1-, 5-, and 7-year survival rates were 95%, 78%, and 70% for empagliflozin 25 mg, 95%, 74%, and 66% for empagliflozin 10 mg, and 94%, 77%, and 69% for dapagliflozin, respectively. Annual emergency department visits were slightly lower with empagliflozin 10 mg and dapagliflozin 10 mg than with empagliflozin 25 mg. A greater proportion of patients on dapagliflozin 10 mg did not experience hospitalization during the 7-year follow-up compared with both doses of empagliflozin, albeit with a small effect size.CONCLUSIONAmong patients with HF and T2DM, SGLT2is are instrumental, and empagliflozin 10 mg remains significantly inferior to dapagliflozin 10 mg and empagliflozin 25 mg in terms of 5- and 7-year ACM.

100 Deals associated with Dapagliflozin/Pioglitazone

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	KR	Boryung Corp.	28 May 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2021	Not Applicable	Type 2 diabetes mellitus with established diabetic nephropathy soluble urokinase-type plasminogen activator receptor (suPAR)	36	Dapagliflozin 10 mg/d	fmysonzprs(whmaawuwgf) = wfdpqjjqij sxblxtzlsx (paxncybhll, -0.72 to 0.36)	Negative	27 Oct 2021
				Placebo	fmysonzprs(whmaawuwgf) = weckwgiqdw sxblxtzlsx (paxncybhll, -0.71 to 0.33)
ASN2019	Not Applicable	Fibrosis urinary Dickkopf-3 (DKK3)	31	Dapagliflozin 10 mg/d	zvjwhboddj(dmppvokysk) = xsowhpsypf hzbhsgegqr (wxajhxahpo, -29.3 to 38.2)	Positive	05 Nov 2019
				Placebo	zvjwhboddj(dmppvokysk) = elgbnpdpdk hzbhsgegqr (wxajhxahpo, 2.2 - 96.4)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dapagliflozin/Pioglitazone

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation